BIOMAT Database Logo BIOMAT Database Logo

Congenital erythroblastic hypoplasia. Treatment of transfusion hemosiderosis with desferrioxamine B. 1968

F J Hildner, and R W Monto, and J W Rebuck

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D006486 Hemosiderosis Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin. Hemosideroses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F J Hildner, and R W Monto, and J W Rebuck
Transfusion hemosiderosis. Report of a case treated with desferrioxamine-B.
June 1965, Journal of the Iowa Medical Society,
F J Hildner, and R W Monto, and J W Rebuck
The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
September 1966, Helvetica paediatrica acta,
F J Hildner, and R W Monto, and J W Rebuck
Treatment of hemodialysis hemosiderosis with desferrioxamine.
January 1982, Transactions - American Society for Artificial Internal Organs,
F J Hildner, and R W Monto, and J W Rebuck
ERYTHROBLASTIC HYPOPLASIA.
June 1964, Canadian Medical Association journal,
F J Hildner, and R W Monto, and J W Rebuck
[Controlled desferrioxamine treatment of congenital anaemia and transfusion siderosis (author's transl)].
August 1978, Deutsche medizinische Wochenschrift (1946),
F J Hildner, and R W Monto, and J W Rebuck
[Desferrioxamine in patients with hemochromatosis and hemosiderosis].
January 1966, Revista do Hospital das Clinicas,
F J Hildner, and R W Monto, and J W Rebuck
[Use of desferrioxamine B in the treatment of post-transfusion hypersiderosis].
January 1965, Marseille medical,
F J Hildner, and R W Monto, and J W Rebuck
[Effect of desferrioxamine B on tissue sections of hemosiderosis of the kidney].
June 1966, Arzneimittel-Forschung,
F J Hildner, and R W Monto, and J W Rebuck
[The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)].
December 1977, [Rinsho ketsueki] The Japanese journal of clinical hematology,
F J Hildner, and R W Monto, and J W Rebuck
Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
July 1976, Clinical nephrology,
Copied contents to your clipboard!